Business
Intellia Therapeutics Enters Lease Agreement to Build Manufacturing Facility for its CRISPR-based Therapies
State-of-the-art GMP manufacturing facility to support preclinical through commercial production of Intellia’s investigational therapiesNew facility in
About this update from Intellia Therapeutics, Inc.
[{"type":"text","content":"State-of-the-art GMP manufacturing facility to support preclinical through commercial production of Intellia’s investigational therapiesNew facility in Waltham, Massachusetts expected to be operational in 2024 CAMBRIDGE, Mass., Feb. 23, 2022 (GLOBE NEWSWIRE) -- Intellia Therapeutics, Inc. (NASDAQ:NTLA), a leading genome editing company focused on developing curative therapies leveraging CRISPR-based technologies, today announced that it has entered into a lease agreement to develop a 140,000-square-foot manufacturing facility in Waltham, Massachusetts, to support the manufacturing of key components for its CRISPR-based investigational therapies. “As Intellia continues to advance a growing number of innovative CRISPR-based medicines, the ability to efficiently and reliably manufacture our products is crucial to our mission of bringing transformational medicines to patients with life-threatening diseases,” said Intellia Chief Technical Officer Eliana Clark, Ph.D. “This new facility is a strategic investment, which in combination with existing capabilities and partnerships, will provide us with significant manufacturing capacity and accelerate the clinical development and future commercial production for our therapeutic candidates.” The new manufacturing facility will be Good Manufacturing Practice (GMP) compliant and support both the preclinical through commercial supply upon regulatory approval for key components of Intellia’s CRISPR-based therapies. Additionally, this new facility will be able to provide capacity and capabilities in support of Intellia’s expanding pipeline and commercial readiness. The new facility, customized for Intellia’s requirements, will be constructed and managed by Alexandria Real Estate Equities, L.P. and is expected to be operational in 2024. Intellia Chief Financial Officer Glenn Goddard went on to comment, “Choosing a long-term lease agreement provides Intellia with greater manufacturing flexibility and only a modest financial upfront requirement compared with building our own facility from the ground up. We look forward to working with Alexandria as they build this new facility.” About Intellia Therapeutics Intellia Therapeutics, a leading clinical-stage genome editing company, is developing novel, potentially curative therapeutics leveraging CRISPR-based technologies. To fully realize the transform...